These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19924525)

  • 1. Adherence and its measurement in phase 2/3 microbicide trials.
    Tolley EE; Harrison PF; Goetghebeur E; Morrow K; Pool R; Taylor D; Tillman SN; van der Straten A
    AIDS Behav; 2010 Oct; 14(5):1124-36. PubMed ID: 19924525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbicide clinical trial adherence: insights for introduction.
    Woodsong C; MacQueen K; Amico KR; Friedland B; Gafos M; Mansoor L; Tolley E; McCormack S
    J Int AIDS Soc; 2013 Apr; 16(1):18505. PubMed ID: 23561044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal microbicides.
    O'Brien RF
    Adolesc Med Clin; 2006 Oct; 17(3):673-85; abstract xi. PubMed ID: 17030285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methodological lessons from clinical trials and the future of microbicide research.
    van der Straten A; Montgomery ET; Hartmann M; Minnis A
    Curr HIV/AIDS Rep; 2013 Mar; 10(1):89-102. PubMed ID: 23184582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
    J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal microbicide preferences among midwestern urban adolescent women.
    Tanner AE; Katzenstein JM; Zimet GD; Cox DS; Cox AD; Fortenberry JD
    J Adolesc Health; 2008 Oct; 43(4):349-56. PubMed ID: 18809132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving topical microbicide applicators for use in resource-poor settings.
    Vail JG; Cohen JA; Kelly KL
    Am J Public Health; 2004 Jul; 94(7):1089-92. PubMed ID: 15226124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "We have our protector": misperceptions of protection against HIV among participants in a microbicide efficacy trial.
    Mantell JE; Morar NS; Myer L; Ramjee G
    Am J Public Health; 2006 Jun; 96(6):1073-7. PubMed ID: 16670239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbicide acceptability research: current approaches and future directions.
    Mantell JE; Myer L; Carballo-Diéguez A; Stein Z; Ramjee G; Morar NS; Harrison PF
    Soc Sci Med; 2005 Jan; 60(2):319-30. PubMed ID: 15522488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical research with topical microbicides as a potential HIV prevention method.
    Van Damme L
    AIDS Read; 2000 Sep; 10(9):552-4. PubMed ID: 11019454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III anti-HIV microbicide trial in Africa and India stopped as preliminary results show gel may increase risk of infection.
    Editorial team
    Euro Surveill; 2007 Feb; 12(2):E070208.6. PubMed ID: 17370954
    [No Abstract]   [Full Text] [Related]  

  • 15. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials.
    Ferrer RA; Morrow KM; Fisher WA; Fisher JD
    AIDS Care; 2010 Aug; 22(8):997-1005. PubMed ID: 20552466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?
    Elias C; Coggins C
    J Womens Health Gend Based Med; 2001 Mar; 10(2):163-73. PubMed ID: 11268299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbicides and HIV prevention: lessons from the past, looking to the future.
    Morris GC; Lacey CJ
    Curr Opin Infect Dis; 2010 Feb; 23(1):57-63. PubMed ID: 19918175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of HIV prevention: prospects for an effective anti-HIV microbicide.
    Nuttall J; Romano J; Douville K; Galbreath C; Nel A; Heyward W; Mitchnick M; Walker S; Rosenberg Z
    Infect Dis Clin North Am; 2007 Mar; 21(1):219-39, x. PubMed ID: 17502237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials.
    de Bruin M; Viechtbauer W
    PLoS One; 2012; 7(8):e44029. PubMed ID: 22970107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.